NCT03639571View on ClinicalTrials.gov

Phase I Study to Assess Irritation, Sensitization and Adhesion of a Novel Ibuprofen 200 mg TEPI Medicated Plaster

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

August 9, 2018

Primary Completion Date

October 25, 2018

Study Completion Date

October 25, 2018

Conditions
Healthy
Interventions
DRUG

Ibuprofen 200 mg TEPI Medicated Plaster

Ibuprofen 200 mg TEPI Medicated Plaster, manufactured by AdhexPharma, France on behalf of Medherant Ltd., UK

OTHER

Placebo TEPI Plaster

Placebo TEPI Plaster, manufactured by AdhexPharma, France on behalf of Medherant Ltd., UK

Trial Locations (1)

Unknown

MHAT, Sofia

Sponsors

Lead Sponsor

Medherant Ltd
All Listed Sponsors
collaborator

Cooperative Clinical Drug Research and Development AG (CCDRD AG)

OTHER

lead

Medherant Ltd

INDUSTRY

NCT03639571 - Phase I Study to Assess Irritation, Sensitization and Adhesion of a Novel Ibuprofen 200 mg TEPI Medicated Plaster | Biotech Hunter | Biotech Hunter